SequelSEC

FibroBiologics, Inc. FBLG

Pharmaceutical Preparations · CIK 0001958777 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$16.65M
Fiscal year ended 2025-12-31
Free cash flow
-$16.66M
Fiscal year ended 2025-12-31

FibroBiologics, Inc. (FBLG) reported net income of -$18.65M for the fiscal year ended 2025-12-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from FibroBiologics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

FibroBiologics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
RevenueUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailable
Operating income-$16.65M-$13.74M-$8.89M-$4.47M
Net income-$18.65M-$11.16M-$16.48M-$5.12M
Research & development$7.41M$4.50M$2.37M$1.15M
Weighted-average diluted sharesshares 44.66Mshares 32.88Mshares 28.23Mshares 28.23M
Pretax incomeUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0
Diluted EPS$-0.42$-0.34$-0.68$-0.18
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable
General & administrative$9.24M$9.23M$6.52M$3.32M
Selling & marketingUnavailableUnavailableUnavailableUnavailable

Balance

FibroBiologics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Cash & equivalents$4.89M$13.98M$9.16M$2.27M
Total assets$9.62M$16.44M$11.82M$4.82M
Current assets$6.35M$14.23M$9.22M$2.62M
Total liabilities$3.46M$13.71M$10.57M$8.82M
Current liabilities$1.76M$12.73M$9.18M$7.07M
Total equity incl. NCI$6.16M$2.74M$1.25M-$4.00M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable$300.00K
GoodwillUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

FibroBiologics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Operating cash flow-$16.39M-$11.90M-$6.40M-$4.07M
Capital expenditures$262.00K$184.00K$495.00KUnavailable
Investing cash flow-$262.00K-$184.00K-$495.00KUnavailable
Financing cash flow$7.56M$16.91M$13.79M$5.92M
Net change in cash-$9.09M$4.82M$6.90M$1.86M
Stock-based compensation$2.69M$2.22M$1.76M$265.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

FibroBiologics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-31
Free cash flow-$16.66M-$12.08M-$6.90MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailable
Current ratio3.61x1.12x1.00x0.37x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FBLG in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-07-31View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.